Protagonist Therapeutics, Inc. (PTGX) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. Protagonist Therapeutics is a biopharmaceutical company focused on peptide therapeutics for inflammatory/immunomodulatory diseases and hematology. Key assets include icotrokinra (licensed to J&J, NDA submitted July 2025 for psoriasis) and rusfertide (co-developed with Takeda, Phase 3 VERIFY trial met primary endpoint in March 2025, NDA expected Q4 2025).
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | Value (in thousands) |
|---|---|
| License & Collaboration Revenue | $33,867 |
| Net Loss | $(46,426) |
| Operating Expenses | $95,218 |
| Research & Development (R&D) | $72,929 |
| General & Administrative (G&A) | $22,289 |
| Interest Income | $14,979 |
| Cash, Cash Equivalents & Marketable Securities | $673,000 |
| Accumulated Deficit | $(386,948) |
| Net Cash Provided by Operating Activities | $96,583 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped 87% to $33.9 million from $259.1 million in the prior year. The 2024 figure included a $254.1 million upfront payment recognition from the Takeda agreement. The 2025 revenue consists primarily of the recognition of a $25.0 million milestone (deemed probable in March 2025) and development services.
- Net Loss vs. Income: The company reported a net loss of $46.4 million compared to net income of $176.7 million in the prior year, driven by the absence of the large upfront revenue recognition and continued R&D investment.
- R&D Expenses: Increased 8% to $72.9 million, primarily due to a $9.8 million increase in pre-clinical and drug discovery expenses for new candidates (PN-881, PN-477), partially offset by a decrease in rusfertide Phase 3 costs.
- Liquidity: Cash and marketable securities increased to $673.0 million from $559.2 million at year-end 2024, bolstered by a $165.0 million milestone payment received from J&J in January 2025.
Outlook, Risks, and Management Commentary
- Regulatory Milestones: J&J submitted an NDA for icotrokinra in July 2025. Protagonist expects to file an NDA for rusfertide in Q4 2025 following positive Phase 3 data.
- Pipeline Expansion: The company nominated PN-881 (IL-17 antagonist) and PN-477 (obesity triple agonist) as development candidates. Phase 1 studies for PN-881 are expected in Q4 2025, and PN-477 in Q2 2026.
- Capital Resources: Management states that existing cash and marketable securities ($673.0 million) are sufficient to fund operations for at least the next 12 months.
- Tax Legislation: The "One Big Beautiful Bill" Act was enacted on July 4, 2025. The company is evaluating the impact of restored bonus depreciation and immediate expensing of R&D costs on its financial statements.
- Risks: Primary risks include the uncertainty of regulatory approvals, the ability to raise additional capital if needed, and the commercial success of collaboration partners (J&J and Takeda).
Investor Verification Checklist
- Verify the timing and probability of the icotrokinra NDA approval by the FDA following the July 2025 submission.
- Confirm the Q4 2025 NDA filing timeline for rusfertide and the specific terms of the Takeda collaboration regarding profit-sharing vs. opt-out rights.
- Monitor the cash burn rate relative to the $673 million liquidity position to assess runway beyond the 12-month guidance.
- Review the impact of the new tax legislation on future effective tax rates and R&D expense recognition.
- Track progress on PN-881 and PN-477 IND-enabling studies and Phase 1 initiation dates.